HEALTHeUNIVERSE, Inc. (HLUN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHEALTHeUNIVERSE, Inc. (HLUN) trades at $0.0001. Healtheuniverse, Inc. is a biotechnology company focused on developing and commercializing biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products. Their focus is on stem cell and regenerative medicine therapies using non-embryonic adult stem cells. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for HLUN: HLUN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
HEALTHeUNIVERSE, Inc. (HLUN) Healthcare & Pipeline Overview
Healtheuniverse, Inc. is a biotechnology company specializing in the research, development, and commercialization of regenerative medicine therapies using non-embryonic adult stem cells. The company also offers consulting services in marketing, business organization, and capital raising, operating within the competitive healthcare and biotechnology sector.
What Is the Investment Thesis for HLUN?
Healtheuniverse, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's focus on stem cell and regenerative medicine offers significant potential for growth, particularly given the increasing demand for advanced therapies in various surgical fields. However, the company's OTC listing and shell risk detection introduce substantial uncertainties. While the company boasts a high gross margin of 96.1% and a profit margin of 8.9%, its market capitalization of $0.00B indicates limited investor confidence. The success of Healtheuniverse hinges on its ability to successfully navigate the regulatory landscape, secure funding for ongoing research and development, and effectively commercialize its products. Investors should carefully consider the company's financial stability, competitive positioning, and the inherent risks associated with OTC-listed companies before making any investment decisions.
Based on FMP financials and quantitative analysis
HLUN Key Highlights
High Gross Margin: Healtheuniverse boasts a gross margin of 96.1%, indicating strong pricing power and efficient cost management in its product development.
- Profit Margin: The company has a profit margin of 8.9%, suggesting profitability in its operations, although further analysis is needed to assess sustainability.
- Stem Cell Focus: Healtheuniverse specializes in stem cell and regenerative medicine therapies, positioning it within a high-growth area of the biotechnology industry.
- Consulting Services: The company diversifies its revenue streams by offering consulting services in marketing, business organization, and capital raising.
- OTC Listing: Healtheuniverse trades on the OTC market, which presents both opportunities and risks due to lower regulatory oversight and liquidity.
Who Are HLUN's Competitors?
HLUN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.62 | -0.12% | $88.4M | 82 5-pillar |
| ICCC ImmuCell Corporation | $10.30 | +0.49% | $93.6M | 78 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.08 | -1.21% | $172M | 75 5-pillar |
| NAGE Niagen Bioscience Inc | $2.44 | +0.25% | $190M | 70 5-pillar |
| QTTB Q32 Bio Inc. | $8.41 | -2.77% | $258M | 67 5-pillar |
| MDXG MiMedx Group, Inc. | $3.88 | -0.64% | $570M | 88 5-pillar |
| ZVRA Zevra Therapeutics, Inc. | $9.72 | -0.94% | $583M | 91 5-pillar |
| CLYM Climb Bio, Inc. | $9.03 | -11.41% | $585M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLUN's Key Strengths?
Proprietary stem cell technology.
- Expertise in regenerative medicine therapies.
- Diversified revenue streams through consulting services.
- Focus on high-growth market segments.
What Are HLUN's Weaknesses?
Limited financial resources.
- OTC listing and associated risks.
- Dependence on regulatory approvals.
- Small market capitalization.
What Are the Key Risks for HLUN?
Clinical trial failures could negatively impact the company's valuation.
- Regulatory delays or rejection of product approvals could hinder growth.
- Intense competition from larger biotechnology companies could erode market share.
- Limited financial resources and dependence on external funding.
- OTC listing and associated risks, including shell risk detection.
What Are HLUN's Competitive Advantages?
- Proprietary stem cell technology.
- Expertise in regenerative medicine.
- Diversified revenue streams through consulting services.
- Focus on specific surgical applications.
What Does HLUN Do?
Healtheuniverse, Inc., founded in 2001 and headquartered in Covina, California, is a biotechnology development company focused on the research, development, and commercialization of a diverse range of products including biopharmaceuticals, biomedicals, nutraceuticals, and cosmeceuticals. The company's core focus lies in stem cell and regenerative medicine therapies, utilizing non-embryonic adult stem cells. These therapies are being developed for applications in various surgical fields, including plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Beyond its biopharmaceutical endeavors, Healtheuniverse, Inc. also provides consulting services to businesses, offering expertise in areas such as marketing, business organization, and capital raising. This dual approach allows the company to diversify its revenue streams while maintaining its commitment to innovation in the biotechnology sector. Healtheuniverse operates within the broader healthcare industry, targeting specific segments with its regenerative medicine solutions and consulting services.
What Products and Services Does HLUN Offer?
- Develops stem cell and regenerative medicine therapies.
- Focuses on non-embryonic adult stem cells.
- Targets applications in plastic and reconstructive surgery.
- Develops therapies for orthopedic surgery.
- Creates solutions for vascular and cardiac surgery.
- Offers products for wound care.
- Provides consulting services in marketing.
- Offers consulting in business organization and capital raising.
How Does HLUN Make Money?
- Develops and commercializes biopharmaceutical products.
- Generates revenue through the sale of biomedical products.
- Offers nutraceutical and cosmeceutical products.
- Provides consulting services to businesses.
What Industry Does HLUN Operate In?
Healtheuniverse, Inc. operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and significant investment in research and development. Healtheuniverse's focus on stem cell and regenerative medicine aligns with key industry trends, but it faces competition from larger, more established players with greater financial resources and broader product portfolios. The company's success will depend on its ability to differentiate its products, secure regulatory approvals, and establish strategic partnerships.
Who Are HLUN's Key Customers?
- Hospitals and surgical centers.
- Patients seeking regenerative medicine therapies.
- Businesses seeking marketing and organizational consulting.
- Investors interested in biotechnology ventures.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
HEALTHeUNIVERSE, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Covina, US. The company is led by CEO Vipul Dev. HLUN has traded publicly since 2013.
HLUN Financials
HLUN Latest News
No recent news available for HLUN.
HLUN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HLUN.
Price Targets
Wall Street price target analysis for HLUN.
HLUN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HLUN; grades run from A+ (80-100) to F (below 30).
Leadership: Vipul Dev
CEO
Vipul Dev serves as the CEO of Healtheuniverse, Inc. His background includes experience in business development, marketing, and finance, with a focus on emerging growth companies. He has a track record of assisting companies in raising capital and expanding their market presence. Vipul Dev's expertise lies in identifying and capitalizing on opportunities in the biotechnology and healthcare sectors. He has a strong understanding of the regulatory landscape and the challenges associated with commercializing new therapies.
Track Record: Under Vipul Dev's leadership, Healtheuniverse, Inc. has focused on developing its stem cell and regenerative medicine therapies. Key milestones include advancing research programs and securing partnerships to expand the company's reach. He has also overseen the company's consulting services, contributing to revenue diversification. His strategic decisions have aimed to position Healtheuniverse for long-term growth in the biotechnology sector.
HLUN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Healtheuniverse, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent regulatory oversight, which can increase investment risk. This tier is often populated by shell companies, companies with distressed financials, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's true financial health and performance.
- Shell Risk: The detection of shell risk indicates a potential for fraudulent activity or lack of legitimate business operations.
- Liquidity Risk: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares at desired prices.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight, increasing the risk of non-compliance and potential legal issues.
- Price Volatility: The OTC market is prone to higher price volatility due to limited liquidity and speculative trading.
- Verify the company's legal standing and registration.
- Investigate the background and experience of the management team.
- Obtain and review any available financial statements and disclosures.
- Assess the company's business model and competitive positioning.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any pending litigation or regulatory actions.
- Consult with a qualified financial advisor before investing.
- Focus on stem cell and regenerative medicine therapies.
- Consulting services to businesses.
- CEO with experience in business development and marketing.
- Development of products for plastic and reconstructive surgery.
- Headquartered in Covina, California.
What Investors Ask About HEALTHeUNIVERSE, Inc. (HLUN) — Healthcare
What do analysts say about HLUN stock?
Currently, there is no readily available analyst coverage for Healtheuniverse, Inc. (HLUN) due to its listing on the OTC market and its small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- Shell risk detected, indicating potential for fraudulent activity.
- Financial data may not be comprehensive or reliable.